Since 2001, DBR Canada Inc. has specialized in services related to the preparation, management, and delivery of reimbursement submissions for prescription drugs (oral, injectable) including mono and combination therapies, immunotherapies, antineoplastic agents, radiopharmaceuticals, gene editing technologies, and biosimilars, with additional experience preparing submissions for medical devices and nutritional products. Through a combination of internal expertise and strategic partnerships, DBR Canada Inc. has the ability to provide clients with complete solutions related to navigating all aspects of the various public and private health technology assessment (HTA) review processes in Canada, including submissions to Canada’s Drug Agency (CDA-AMC), the Institut national d’excellence en santé et en services sociaux (INESSS), Federal-Provincial-Territorial (F/P/T) Drug Programs and Cancer Agencies, and private payers. The strength and quality of our services is based on our ability to assemble senior level project teams where each team member typically has 20 years or more experience within their respective discipline. Key areas of expertise amongst team members range from overall submission preparation, management, and delivery to the ability to perform systematic literature reviews, clinical evidence summarization, indirect treatment comparisons, pharmacoeconomics, and budget impact analysis. The power of this dynamic cross functional group is what facilitates DBR Canada Inc.’s “small but mighty” ability to help support every aspect of a client’s needs when it comes to meeting the submissions requirements of the various public and private payers across a wide range of submission types from new drug, new medical device or new nutritional product submissions, to new indications, formulations, strengths or formats of already approved products.
Back to Sponsors